8:00 am
Virtual Coffee & Online Registration

8:45 am Chair’s Opening Remarks

  • Kirk Tanner Chief Scientific Officer , National Brain Tumor Society

9:00 am An In-Depth Overview of Current Research Strategies for Glioblastoma & Barriers to Progress

  • Patrick Wen Director, Center For Neuro-Oncology, Dana-Farber/Brigham & Women’s Cancer Center


  • Overview of changes in the classification and definition of glioblastoma
  • Summary of the major therapeutic strategies currently under
  • Discuss barriers to progress and strategies to address these

9:30 am Overcoming the Blood Brain Drug Delivery Hurdle with Tumor Treating Fields (TTFields)

  • Carsten Hagemann Head of the Tumorbiology, Laboratory University Hospital Wuerzburg


  • Evaluate the effect of TTFields on an in vitro blood brain barrier (BBB) model
  • Investigate TTFields induced BBB opening in vivo
  • Discuss the potential of TTFields to improve treatment of glioblastoma and other CNS diseases by opening the BBB

9:50 am I’m Still Here – A Long-Term Survivor’s Perspective


  • Explore a patient’s GBM story and drug treatments
  • Learn how to diagnose GBM patients and what’s involved
  • Deep dive into OurBrainBank – a patient-driven movement to turn glioblastoma from terminal to treatable


10:20 am Optimize the Role of Immunotherapy for Treatment of Glioblastoma


  • Outline the historical and current understanding of the mechanisms of
    immune responses against glioblastoma
  • Discuss the common challenges of designing and evaluating clinical
    trials of immunotherapy for glioblastoma
  • Elucidate the considerations of timing, sequence, and tumor/patient
    heterogeneity in developing combination immunotherapy/vaccine trials
    for glioblastoma

10:50 am MDNA55, an IL4-Guided Toxin in Recurrent GBM: Phase 2b Results & Use of an External Control Arm in a Registration Trial


  • Updated results from the Phase 2b clinical trial: results show improved 2-year survival rate and long-term tumor control (progression-free survival)
  • Use of a propensity matched External Control Arm (ECA) demonstrates potential utility for go/no go decisions and reduces risk in a registration trial
  • Presentation of a novel hybrid-design incorporating an ECA in a planned recurrent GBM registration trial

11:10 am
Morning Break & Virtual Speed Networking


11:40 am An Exclusive Update on Neoantigen Vaccination for Glioblastoma

  • David Reardon Clinical Director, Center for NeuroOncology, Dana-Farber Cancer Institute


  • Describe rationale for targeting neoantigens for anti-tumor vaccination
  • Summarize therapeutic development of neoantigen vaccination for
    oncology to date
  • Overview results of neoantigen vaccination application for glioblastoma
  • Enhance next steps to optimize neoantigen vaccination for glioblastoma

12:10 pm Examine the Absolute Utilization of Vaccine Immunotherapy to Treat Glioblastoma

  • Adilia Hormigo Director Neuro-Oncology Division, Icahn School of Medicine, Mount Sinai & The Tisch Cancer Institute


  • Explore immunotherapy with vaccines that can be used to treat GBM
  • Evaluate personalized vaccines and off-the-shelf vaccines
  • Discuss use of vaccines in combination treatments for GBM

12:40 pm Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses


  • Studies using a intracellular targeting technology have shown promising clinical responses in newly diagnosed GBM subjects
  • Phase I median overall survival for treated subjects was >41 months in newly diagnosed GBM in a small cohort of patients (N=21)
  • Animal modeling using pDNA in a cell-free approach may provide an alternative to cell therapy and potentially expand the candidate patient population

12:50 pm
Lunch Break & Virtual Networking

1:50 pm PANEL DISCUSSION: Evaluate the Current Challenges, Approaches and Opportunities in Treating Glioblastoma

  • Michael Lim Professor & Chair, Department of Neurosurgery Professor, Stanford University School of Medicine
  • Jann Sarkaria Professor of Radiation Oncology, Mayo Clinic
  • Patrick Wen Director, Center For Neuro-Oncology, Dana-Farber/Brigham & Women’s Cancer Center
  • Jing Li Associate Professor, Karmanos Cancer Institute


  • A year on from the inaugural GBM Drug Development meeting: What have we learnt?
  • How can drug developers cut to the real barriers, and debate what is truly required to break through to successful treatments for GBM?
  • The impact of COVID-19 and its repercussions on existing clinical trials

2:35 pm Exhausted T-cells for GBM Immunotherapy: An Exclusive Look at Fresh GBM Clinical Trial Results

  • Michael Lim Professor & Chair, Department of Neurosurgery Professor, Stanford University School of Medicine


  • Discuss concept of exhaustion in T-cells
  • Examine GBM specific immunosuppression
  • Evaluate results from recent Glioblastoma patient clinical trials

3:05 pm Empower the Immune System to Treat Glioblastoma: DNA as Medicine


  • Explore DNA medicines that have the potential to create robust,
    antigen-specific T cell responses
  • Evaluate Inovio’s DNA medicine, INO-5401 has promising, early data in
    GBM showing early efficacy, and immunogenicity
  • Discuss Inovio’s DNA medicine, its technology, and other promising
    approaches to GBM therapy will be discussed

3:35 pm Updated Clinical Results in Recurrent Glioblastoma for VBI1901 – A Therapeutic Vaccine Targeting CMV-Associated Cancers

  • Dave Anderson Senior Vice President, Research, VBI Vaccines, Inc


  • Explore VBI-1901 targets CMV-antigens that are highly expressed in
  • Study a Phase I/II study that has demonstrated improved OS among
    vaccine responders
  • Assess a novel biomarker may predict patients most likely to derive
    clinical benefit from VBI-1901

4:05 pm
Afternoon Break & Virtual Networking

4:35 pm SurVaxM, First-of-its-Kind: A Survivin-Targeted Vaccine for Glioblastoma


  • Explore how SurVaxM induces strong immune responses involving more
    than one arm of the immune system
  • Assess how strong immune responses to SurVaxM are associated with
    longer survival
  • Discuss OS and PFS, and how they may be extended in patients with
    newly diagnosed glioblastoma by treatment with SurVaxM

5:05 pm Special Look At Phase 1b Imvax Study to Assess the Safety and Efficacy of IGV-001


  • Explore highest exposure cohort yielded significantly higher proinflammatory cytokine serum levels; by 23rd patient, clear that clinical and radiographic responses were superior in this cohort and protocol amended for ethical reasons to stop randomization.
  • Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over historical controls.
  • Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached

5:35 pm A Complete Review of Autologous Dendritic Cells Loaded with Antigens from Self-Renewing Autologous Glioblastoma Cells


  • Examine the importance of neoantigens and antigens from tumor initiating cells as an excellent source of antigens for patient-specific vaccines
  • Evaluate the advantage of injections of autologous dendritic cells with tumor antigens ex vivo compared to injecting tumor antigens
  • A look at enrollment completed for a phase II trial testing for a vaccine, along with chemotherapy and radiation therapy for primary GBM

6:05 pm PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets


  • Examine the current treatment options and emerging targeted therapies
  • If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to GBM patients?
  • Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?

6:50 pm
Chair’s Closing Remarks
  • Kirk Tanner Chief Scientific Officer , National Brain Tumor Society

7:00 pm
End of Day One of the 2nd Glioblastoma Drug Development Summit